Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
October 10, 2008
 
Industry Categories  
News by Country  
News by MSA  
Today's News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for January 30, 2006 Subscribe to this News Feed    
 

Help Dr. Hotze Protect a Woman’s Right to Bio-Identical Hormones

Natural Hormone Treatment Being Attacked

(PRWEB) January 30, 2006 -- Steven Hotze, M.D., best selling author of “Hormones, Health, and Happiness,” is leading a wellness revolution around the country educating women on bio-identical hormones, now a big drug company is trying to squash a woman’s right to choose natural hormones over synthetic ones.

Dr.Hotze says “Wyeth Pharmaceuticals wants the FDA to take away your right to choose safe, effective and natural, bio-identical hormones by regulating your choice of health treatments.”

Wyeth, the maker of Premarin and Prempro, filed a "Citizens Complaint" with the FDA on October 16, 2005, requesting that the FDA effectively prohibit compounding pharmacies from providing bio-identical hormones to their patients. “This would mean you could no longer get bio-identical hormones,” said Hotze.

Since the 2002 Women's Health Initiative (WHI), which demonstrated Premarin and Prempro caused a significant increase in breast cancer, blood clots to the lungs, heart attacks and strokes; Wyeth has seen a dramatic decline in the sale of their products.

“Tens of thousands of women have forsaken synthetic hormones for bio-identical hormones, Hotze said, Wyeth is simply trying to stop its losses and regain its market share.”

The FDA collects no drug user fees from compounding pharmacies because they are regulated by the states, not the federal government. However, the FDA does receive drug user fees, totaling over $300,000,000 in 2004, from the pharmaceutical companies for the drugs they sell. The fewer drugs that Wyeth sells, the less money the FDA makes. Dr. Hotze says that the FDA wants to eliminate compounding pharmacies as well.

Wyeth, like all the major pharmaceutical companies, contributes billions of dollars to various medical societies and patient advocacy organizations. So it is not surprising that many of these organizations have written responses to the FDA in support of Wyeth's complaint.

“Wyeth can and must be defeated in its attempt to restrict patients' rights to choose to safe, effective and natural treatments using bio-identical hormones,” says Hotze.

You can voice your opposition to the Wyeth Complaint by going directly to the FDA comment link below and telling the FDA your story. The comment filing period ends on April 4, 2006 at which time the FDA will make its decision.
The FDA Link is:
http://www.accessdata.fda.gov/scripts/oc/dockets/comments/commentsmain.cfm?EC_DOCUMENT_ID=794&SUBTYP=NEXT&CID=&AGENCY=FDA


Dr. Hotze urges, “Your ability to continue to choose your treatment depends upon our success in blocking Wyeth and the FDA in their plan to eliminate bio-identical hormones.”

To set up an interview with Dr. Hotze, please contact Nanette Noffsinger at 615-776-4230.

###

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Nanette Noffsinger
MEDIA CONSULTANT
615-776-4230
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright